±Þ¼ºÀü°ñ¼ö±¸¼º¹éÇ÷º´ ȯÀÚ¿¡¼ all-trans retinoic acid (ATRA)ÀÇ ºÐÈÁõÈıº ¹ß»ý°ú À§ÇèÀÎÀÚ ºÐ¼®
Incidence and Risk Factors for All-Trans Retinoic Acid-Induced Differentiation Syndrome in Acute Promyelocytic Leukemia
º´¿ø¾à»çȸÁö 2018³â 35±Ç 1È£ p.39 ~ p.47
Á¤°í¿î(Jung Go-Un) - °¡Å縯´ëÇб³ ¼¿ï¼º¸ðº´¿ø ¾àÁ¦ºÎ
¹Ú¾Ö·É(Park Ae-Ryoung) - °¡Å縯´ëÇб³ ¼¿ï¼º¸ðº´¿ø ¾àÁ¦ºÎ
±è¼øÁÖ(Kim Soon-Joo) - °¡Å縯´ëÇб³ ¼¿ï¼º¸ðº´¿ø ¾àÁ¦ºÎ
³ªÇö¿À(La Hyen-O) - °¡Å縯´ëÇб³ ¾àÇдëÇÐ
ÀÌÁ¤¿¬(Rhie Sandy Jeong) - ÀÌÈ¿©ÀÚ´ëÇб³ ¾àÇдëÇÐ
Abstract
Background : Acute promyelocytic leukemia (APL) is a unique subtype of acute myeloid leukemia (AML). All-trans retinoic acid (ATRA) triggers APL cells to differentiate into mature granulocytes. Differentiation syndrome (DS) otherwise known as retinoic acid syndrome is a complication associated with the treatment of APL with ATRA. DS is characterized by unexplained fever, weight gain, peripheral edema, dyspnea, pleuropericardial effusion, hypotension, and acute renal failure. Incidence of DS ranges from 2-27%, and detailed knowledge about DS is limited. The purpose of this study is to investigate the prevalence and risk factors of DS in APL patients.
Methods : This study was retrospectively conducted on patients diagnosed with APL that received initial oral administration of ATRA January 2012-June 2015. This study analyzed incidence, onset, clinical signs and symptoms, management, and risk factors of DS.
Results : Among 95 patients, 29 patients (30.5%) experienced DS, 12 with moderate form (12.6%) and 17 with severe form (17.9%). The first peak occurred during the first week of ATRA treatment. The most frequent clinical manifestations of DS were edema (82.8%), pleuropericardial effusion (75.9%), dyspnea (65.5%), and fever (62.1%). Intravenous dexamethasone was administered in 82.8% of patients with DS. ATRA was discontinued in 93.1% of patients with DS. The univariate analysis of prognostic factors identified the following characteristics as significantly associated with DS: blood urea nitrogen (BUN) ¡Ã20 mg/dL and lactate dehyrogenase (LDH) ¡Ã900 U/L. Upon multivariate analysis, abnormal levels of BUN remained independent prognostic factors for DS (OR 4.06; 95% CI 1.19-13.79; p=0.03).
Conclusion : In this study, high level of BUN is one of the risk factors that can predict the potential side effects of DS. We recommend the use of steroid to prevent DS for people taking ATRA with abnormal level of BUN.
Å°¿öµå
Acute promyelocytic leukemia (APL), All-trans retinoic acid (ATRA), Differentiation syndrome (DS)
KMID :
0869620180350010039
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸
À¯È¿¼º°á°ú(Recomendation)
The use of steroid to prevent different syndrome for people taking ATRA with abnormal level of BUN.